Literature DB >> 7867179

Coronary stenting decreases restenosis in lesions with early loss in luminal diameter 24 hours after successful PTCA.

A E Rodriguez1, O Santaera, M Larribau, M Fernandez, R Sarmiento, J B Newell, G S Roubin, I F Palacios.   

Abstract

BACKGROUND: Early loss of minimal luminal diameter (MLD) after successful percutaneous transluminal coronary angioplasty (PTCA) is associated with a higher incidence of late restenosis. METHODS AND
RESULTS: Sixty-six patients (66 lesions) with > 0.3 mm MLD loss at 24-hour on-line quantitative coronary angiography were randomized into two groups: 1, Gianturco-Roubin stent (n = 33) and 2, Control, who received medical therapy only (n = 33). All lesions were suitable for stenting. Baseline demographic, clinical, and angiographic characteristics were similar in the two groups. Restenosis (> or = 50% stenosis) for the overall group occurred in 32 of 66 patients (48.4%) at 3.6 +/- 1-month follow-up angiography. Restenosis was significantly greater in group 2 than in group 1 (75.7% versus 21.2%, P < .001). Vascular complications (21.2% versus 0%) and length of hospital stay (7.3 +/- 1 versus 2.4 +/- 0.5 days, P < .01) were higher for the stent group. Although at follow-up there were no differences in mortality or incidence of acute myocardial infarction between the two groups, patients in the control group had a higher incidence of repeat revascularization procedures (73% versus 21%, P < .001).
CONCLUSIONS: In patients with successful PTCA but reduced luminal diameter demonstrated by repeat angiography at 24 hours, the Gianturco-Roubin stent appears to reduce angiographic restenosis at follow-up.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7867179     DOI: 10.1161/01.cir.91.5.1397

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Impact of the "stent-when-feasible" policy on in-hospital and 6-month success and complication rates after coronary angioplasty: single-center experience with 17,956 revascularization procedures (1993-1997).

Authors:  P Angelini; W K Vaughn; M Zaqqa; J M Wilson; R D Fish
Journal:  Tex Heart Inst J       Date:  2000

Review 2.  Will drug-eluting stents replace coronary artery bypass surgery?

Authors:  Ross M Reul
Journal:  Tex Heart Inst J       Date:  2005

Review 3.  In vitro models of angiogenesis.

Authors:  Areck A Ucuzian; Howard P Greisler
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

4.  The acute effect of stenting with the nitinol self-expanding coil stent: preliminary experience.

Authors:  A Roguin; R Beyar
Journal:  Int J Card Imaging       Date:  1997-12

5.  Plaque Tissue Components Obtained from De Novo Lesions may Predict Restenosis after Directional Coronary Atherectomy.

Authors:  Kentaro Arakawa; Hatsue Ishibashi-Ueda; Hiroyuki Hao; Yoshihiko Ikeda; Atsushi Kawamura
Journal:  Ann Vasc Dis       Date:  2010-07-21

6.  Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial).

Authors:  A E Rodríguez; M Rodríguez Alemparte; C F Vigo; C Fernández Pereira; C Llauradó; D Vetcher; A Pocovi; J Ambrose
Journal:  Heart       Date:  2005-03-17       Impact factor: 5.994

7.  Coronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal LAD stenosis: results from the ERACI II study.

Authors:  A Rodriguez; M Rodríguez Alemparte; J Baldi; J Navia; A Delacasa; D Vogel; R Oliveri; C Fernández Pereira; V Bernardi; W O'Neill; I F Palacios
Journal:  Heart       Date:  2003-02       Impact factor: 5.994

Review 8.  Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction.

Authors:  Todd J Anderson
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

Review 9.  Absorbable stent: focus on clinical applications and benefits.

Authors:  Nieves Gonzalo; Carlos Macaya
Journal:  Vasc Health Risk Manag       Date:  2012-02-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.